GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » EV-to-EBIT
中文

Medicenna Therapeutics (TSX:MDNA) EV-to-EBIT : -6.34 (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Medicenna Therapeutics's Enterprise Value is C$111.95 Mil. Medicenna Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-17.64 Mil. Therefore, Medicenna Therapeutics's EV-to-EBIT for today is -6.34.

The historical rank and industry rank for Medicenna Therapeutics's EV-to-EBIT or its related term are showing as below:

TSX:MDNA' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.09   Med: 0   Max: 0.49
Current: -6.35

During the past 9 years, the highest EV-to-EBIT of Medicenna Therapeutics was 0.49. The lowest was -15.09. And the median was 0.00.

TSX:MDNA's EV-to-EBIT is ranked worse than
100% of 444 companies
in the Biotechnology industry
Industry Median: 8.185 vs TSX:MDNA: -6.35

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Medicenna Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was C$7.49 Mil. Medicenna Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-17.64 Mil. Medicenna Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -235.58%.


Medicenna Therapeutics EV-to-EBIT Historical Data

The historical data trend for Medicenna Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics EV-to-EBIT Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only -4.09 -15.87 -13.41 -3.17 -1.70

Medicenna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -1.70 -0.91 -0.12 -0.42

Competitive Comparison of Medicenna Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Medicenna Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's EV-to-EBIT falls into.



Medicenna Therapeutics EV-to-EBIT Calculation

Medicenna Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=111.946/-17.644
=-6.34

Medicenna Therapeutics's current Enterprise Value is C$111.95 Mil.
Medicenna Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-17.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicenna Therapeutics  (TSX:MDNA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Medicenna Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-17.644/7.48975
=-235.58 %

Medicenna Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was C$7.49 Mil.
Medicenna Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-17.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicenna Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics (TSX:MDNA) Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines